The suit was filed in the US District Court for the Eastern District of Missouri and seeks monetary damages as well as a permanent injunction against Synergetics' sale of its Quick Disconnect laser probes and its Quick Disconnect laser probe adapter, as well as the manufacture of a variety of products Iridex says infringe on the patent.
Iridex's EndoProbe products are used during endophotocoagulation, a surgical procedure using a laser to treat intraocular structures. It is often used to treat diabetic retinopathy, retinal breaks and detachments.
"Over the years, Iridex has invested significantly in its intellectual property, as evidenced by the fact that we have 17 issued patents and at least three others in the application process," said Barry G. Caldwell, president and CEO of Iridex, yesterday. "Although discussions with Synergetics have been ongoing for some time regarding this infringement, those discussions have proven to be unproductive. As a result, we have filed this lawsuit today."
For more information, visit: www.iridex.com